Cecilia Brown

DocwireNews

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II extension of indication for amivantamab (Rybrevant) in combination with carboplatin and pemetrexed chemotherapy, according to an announcement from Janssen-Cilag International NV, a Johnson &amp; Johnson company.The recommended extension of indication for the treatment for adults with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations after patients experience failure of prior therapy, including an EGFR tyrosine kinase inhibitor.Amivantamab is a fully human EGFR-MET bispecific antibody. The European Commission previously granted conditional marketing authorization of amivantamab in December 2021 as a treatment for advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.&ldquo;Today&rsquo;s positive CHMP opinion is welcome news and demonstrates the results of our deep commitment to transforming outcomes for patients with NSCLC,&rdquo; Kiran Patel, MD, Vice President of Clinical Development in Solid Tumours at Johnson &amp; Johnson Innovative Medicine, said in a statement. &ldquo;Amivantamab has already shown positive outcomes in treating patients with other EGFR mutations, and we now look forward to the next steps in making it available to further patients with common EGFR mutations after progression on osimertinib.&rdquo;The CHMP recommendation for amivantamab is supported by data from the phase 3 MARIPOSA-2 study, which evaluated the efficacy and safety of amivantamab and chemotherapy in patients with locally advanced or metastatic EGFR ex19del or L858R substitution NSCLC who had disease progression on or after treatment with osimertinib, officials said in the release.The arm of MARIPOSA-2 that evaluated amivantamab plus chemotherapy met its primary end point, reducing the risk of disease progression or death by 52%. The median progression-free survival (PFS) was 6.3 months in those receiving amivantamab plus chemotherapy, compared with 4.2 months in those receiving chemotherapy alone (hazard ratio [HR], 0.48; P&lt;.001).A medical oncologist weighed in on what the recent regulatory action means for patients and clinicians.&ldquo;Resistance mechanisms after disease progression on osimertinib are diverse and polyclonal, with up to half being EGFR and MET-based alterations. There are no targeted therapies approved for the post-osimertinib setting, and outcomes with the current standard-of-care, platinum-based chemotherapy are poor,&rdquo; Antonio Passaro, MD, PhD, a medical oncologist in the Division of Thoracic Oncology at the European Institute of Oncology, said in a statement. &ldquo;The combination of amivantamab and chemotherapy offers renewed hope and a new standard of care for these patients, with improvements observed in response rates, [PFS], and intracranial efficacy, even in patients with previously untreated brain metastases.&rdquo;The combination therapy also showed an objective response rate (ORR) of 64%, nearly double the ORR of 36% observed in the patients receiving chemotherapy alone. In addition, the MARIPOSA-2 study showed that amivantamab plus chemotherapy reduced the risk of intracranial progression or death by 45% compared with chemotherapy alone, with a median intracranial PFS of 12.5 months in those receiving the combination, significantly higher than the median intracranial PFS of 8.3 months in those receiving chemotherapy alone (HR, 0.55; P=.001). These results show that amivantamab combination regimens &ldquo;may provide intracranial activity,&rdquo; which is &ldquo;critical for a disease where nearly 30% of patients develop brain metastases,&rdquo; officials said in the announcement.The safety profile of amivantamab plus chemotherapy is &ldquo;consistent with that of its individual components,&rdquo; according to officials. Adverse events (AEs) of grade 3 or higher, &ldquo;mainly due to hematologic toxicities,&rdquo; were reported by 72% of patients treated with amivantamab plus chemotherapy and 48% of those who received chemotherapy alone.The most common AEs of grade 3 or higher included neutropenia, thrombocytopenia, anemia, and leukopenia. Serious treatment-emergent AEs were reported by 32% of patients treated with amivantamab plus chemotherapy and 20% of those receiving chemotherapy alone. Among the patients receiving amivantamab plus chemotherapy, infusion-related reactions occurred in 58%. Treatment-related AEs leading to death occurred in 2% of patients receiving amivantamab plus chemotherapy and 1% of those receiving chemotherapy alone.In line with EMA regulations for new medicines, amivantamab is subject to additional monitoring, officials said in the announcement.Source: <a href="https://www.jnj.com/media-center/press-releases/chmp-recommends-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-nsclc-after-failure-of-prior-therapy">Johnson &amp; Johnson</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

CHMP Recommends Amivantamab Plus Chemotherapy for Certain Patients With Advanced EGFR-Mutated NSCLC

Non-Small Cell Lung Cancer

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a Type II extension of indication.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe